FDA Emphasizes “Deregulatory” Efforts In Mobile Medical Apps Final Guidance
This article was originally published in The Gray Sheet
In a long-awaited final guidance, FDA affirmed its plan to practice enforcement discretion for most mobile medical apps, except those applications that present the same risks as conventional FDA-regulated devices. Some digital health stakeholders praised the guidance, while others wished FDA has waited.
Register for our free email digests: